Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells

  • M. I. Colnaghi


Over the past years intense efforts have been made to identify tumor specific or tumor associated markers which could be immunogenic in humans and animals. A considerable amount of data, which at least proves the existence of tumor associated antigens in humans, has been collected. Immunological techniques applied to diagnosis in oncology have allowed improvement, both in terms of sensitivity and specificity, in the area of pathology as well as in the laboratory and in nuclear medicine. More recently, the use of monoclonal antibodies (MAbs) derived by somatic hybridization [1] has allowed further improvement of results obtained with conventional antisera and opened new pathways in the field of research. In fact, these reagents possess a peculiar characteristic, that is, monospecificity, which makes them particularly suitable for immunological applications where the target of the immune response, the putative tumor antigen, is often undefined, possibly poorly immunogenic and difficult to identify.


Ovarian Carcinoma Human Ovarian Carcinoma Cell Human Ovarian Carcinoma Cell Line Ovarian Carcinoma Patient Bispecific Monoclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kühler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 246, 495–7.CrossRefGoogle Scholar
  2. 2.
    Colcher, D., Milenic, D., Roselli, M. et al. (1989) Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res., 49, 1738–45.PubMedGoogle Scholar
  3. 3.
    Liu, A.Y., Robinson, R.R., Hellström, K.E. et al. (1987) Chimeric mouse-human IgCl antibody that can mediate lysis of cancer cells. Proc. Natl Acad. Sci. USA, 84, 3439–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Miotti, S., Canevari, S., Ménard, S. et al. (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.Int. J. Cancer, 39, 297–303.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson, B.S., Imai, K., Natali, P.C. and Ferrone, S. (1981) Distribution and molecular characterization of a cell surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int. J. Cancer, 28, 293–300.PubMedCrossRefGoogle Scholar
  6. 6.
    Dillman, R.O. (1990) Human antimouse and antiglobulin responses to monoclonal antibodies. Immunoconj. Radiopharm., 3,1–15.Google Scholar
  7. 7.
    Adair, J.R. (1992) Engineering antibodies for therapy. Immunol. Rev., 130, 5–400.PubMedCrossRefGoogle Scholar
  8. 8.
    Orlandi, R., Gussow, D.H., Jones, P.T. and Winter, G. (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 86, 3833–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenberg, S.A. (1992) The immunotherapy and gene therapy of cancer.J. Clin. Pathol, 10, 180–99.Google Scholar
  10. 10.
    Roosnek, E. and Lanzavecchia, A. (1989) Triggering T cells by otherwise inert hybrid anti-CD3/anti-tumor antibodies requires encounter with the specific target cell. J. Exp. Med., 170,297–302.PubMedCrossRefGoogle Scholar
  11. 11.
    Lanzavecchia, A. and Scheidegger, D. (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol, 17,105–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Perez, P., Hoffman, R.W., Titus, J.A. and Segal, D.S. (1986) Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 cross linked to anti-target antibodies. J. Exp. Med., 163,166–78.PubMedCrossRefGoogle Scholar
  13. 13.
    Staerz, U. and Bevan, M.J. (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl Acad. ScL USA, 83,1453–7.CrossRefGoogle Scholar
  14. 14.
    Mezzanzanica, D., Canevari, S., Ménard, S. et al. (1988) Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int. J. Cancer, 41, 609–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Glennie, MJ., McBride, H.M., Worth, A.T. and Stevenson, G.T. (1987) Preparation and performance of bispecific F(ab02 antibody containing thioether-linked Fab’ fragments. J.Immunol, 139, 2367–75.PubMedGoogle Scholar
  16. 16.
    Jung, G., Honsik, C.J., Reisfeld, R.A. and Muller-Eberhard, H.J. (1986) Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. Proc. Natl. Acad. Sci. USA, 83, 4479–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Pupa, S.M., Canevari, S., Fontanelli, R. et al. (1988) Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int. J. Cancer, 42, 455–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Coney, L.R., Tomassetti, A., Carayannopoulos, L. et al. (1991) Cloning of a tumor-associated antigen: MOvl8 and MOvl9 antibodies recognize a folate-binding protein. Cancer Res., 51, 6125–32.PubMedGoogle Scholar
  19. 19.
    Buraggi, G.L., Crippa, F., Landoni, L. et al. (1988) A new monoclonal antibody (MOvl8) against ovarian cancer for imaging and therapy. In Radioactive Isotopes in Clinical Medicine and Research, (eds. R. Hoffer and H. Bergman), Schattauer, Stuttgart, pp. 57–62.Google Scholar
  20. 20.
    Crippa, F., Buraggi, G.L., Di Re, al. (1991) Radioimmunoscintigraphy of ovarian cancer with the MOvl8 monoclonal antibody.Eur. J. Cancer, 27, 724–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Segal, D.M., Qian, J., Titus, J.A. et al. (1992) Targeted cytokine production. Int. J. Cancer, 52 (Suppl), 36–8.Google Scholar
  22. 22.
    Mezzanzanica, D., Neblock, D.S., Garrido, M.A. et al. (1990) In vivo retargeting of human T cells against human ovarian carcinoma by bifunctional F(ab’)2 antibodies. Antib. Immun. Radiopharm., 3, 81Google Scholar
  23. 23.
    Nitta, T., Sato, K., Yagita, H. et al. (1990) Preliminary trial of specific targeting therapy against malignant glioma.Lancet, 335, 368–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Bolhuis, R.L.H., Lamers, C.H.J., Goey, H.S. et al. (1992) Adoptive immunotherapy of ovarian carcinoma with Bs-MAb targeted lymphocytes. A multicenter study. Int. J. Cancer, 7, 78–81.Google Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • M. I. Colnaghi

There are no affiliations available

Personalised recommendations